

BIOSIMILARS: A Safe & Effective **Option for Patients**

In the U.S., biosimilar usage and approvals are on the rise; access to these safe, effective treatments offer patients improved health outcomes. For more information, visit www.biosimilarscouncil.org.



A biosimilar is a biologic medicine that is

highly similar

to a brand biologic medicine.



FDA has approved ~10 biosimilars¹ to treat patients suffering from RA, Crohn's Disease, cancer, psoriasis and other conditions;

more in development^{2,3}



In Europe, ~35 biosimilars available in at least 8 therapeutic classes⁴



Same safety and efficacy

as their biologic

counterpart







Same mechanism

of action



Rigorous FDA testing and review; Less cost to patients and the health system



Companies that manufacture biosimilars are committed to providing safe, effective products

Biosimilars are

safe, effective, more affordable and offer improved patient access.









Visit us:









@biosimscouncil

References

- 1. Center for Drug Evaluation and Research. Available at: http://bit.ly/2j3WkRt. Accessed December 7, 2017.
- 2. Biosimilars Implementation: Testimony of Janet Woodcock, M.D. to the U.S. House of Representatives February 4, 2016. Available at: http://bit.ly/2nmE2bc. Accessed March 13, 2017. 3. Biosimilars to Drive Modern Manufacturing Approaches. Available at: http://bit.ly/2nmE2bc. Accessed March 13, 2017.
- 4. Biosimilars Approved in Europe. Available at: http://bit.ly/2vY8hvt. Accessed August 23, 2017.